Publication: Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs
Issued Date
2020-04-11
Resource Type
ISSN
15364844
10780998
10780998
Other identifier(s)
2-s2.0-85083623678
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Inflammatory Bowel Diseases. Vol.26, No.5 (2020), 678-686
Suggested Citation
Raditya Iswandana, Bao Tung Pham, Su Suriguga, Theerut Luangmonkong, Louise A. Van Wijk, Yvette J.M. Jansen, Dorenda Oosterhuis, Henricus Antonius Maria Mutsaers, Peter Olinga Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs. Inflammatory Bowel Diseases. Vol.26, No.5 (2020), 678-686. doi:10.1093/ibd/izz329 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/54605
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs
Other Contributor(s)
Abstract
© 2020 Crohn's & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. Background: Intestinal fibrosis is a hallmark of Crohn's disease. Here, we investigated the impact of several putative antifibrotic compounds on the expression of fibrosis markers using murine precision-cut intestinal slices. Methods: Murine precision-cut intestinal slices were cultured for 48 hours in the presence of profibrotic and/or antifibrotic compounds. The fibrotic process was studied on gene and protein level using procollagen 1a1 (Col1α1), heat shock protein 47 (Hsp47), fibronectin (Fn2), and plasminogen activator inhibitor-1 (Pai-1). The effects of potential antifibrotic drugs mainly inhibiting the transforming growth factor β (TGF-β) pathway (eg, valproic acid, tetrandrine, pirfenidone, SB203580, and LY2109761) and compounds mainly acting on the platelet-derived growth factor (PDGF) pathway (eg, imatinib, sorafenib, and sunitinib) were assessed in the model at nontoxic concentrations. Results: Murine precision-cut intestinal slices remained viable for 48 hours, and an increased expression of fibrosis markers was observed during culture, including Hsp47, Fn2, and Pai-1. Furthermore, TGF-β1 stimulated fibrogenesis, whereas PDGF did not have an effect. Regarding the tested antifibrotics, pirfenidone, LY2109761, and sunitinib had the most pronounced impact on the expression of fibrosis markers, both in the absence and presence of profibrotic factors, as illustrated by reduced levels of Col1α1, Hsp47, Fn2, and Pai-1 after treatment. Moreover, sunitinib significantly reduced Hsp47 and Fn2 protein expression and the excretion of procollagen 1. Conclusions: Precision-cut intestinal slices can successfully be used as a potential preclinical screening tool for antifibrotic drugs. We demonstrated that sunitinib reduced the expression of several fibrosis markers, warranting further evaluation of this compound for the treatment of intestinal fibrosis.